SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Biocon sets price band for Syngene's IPO

16 Jul 2015 Evaluate

Biocon has set the price band for an initial public offering of its clinical research services arm, Syngene International, at Rs 240-250 a share. Syngene’s IPO shall open for subscription on July 27 and close on July 29.

Earlier in June, Syngene received the Foreign Investment Promotion Board (FIPB) approval for raising foreign investment in the company to 44 per cent from the earlier approved 10 per cent. The equity shares of Syngene are proposed to be listed on BSE and the National Stock Exchange (NSE).

Biocon is India’s largest and Asia’s leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

424.90 -0.25 (-0.06%)
05-Aug-2026 10:39 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1942.50
Dr. Reddys Labs. 1165.20
Cipla 1450.50
Lupin 2382.00
Zydus Lifesciences 1112.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: